Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
F H ValoneM Mrozek-Orlowski

Abstract

MDX-210 is a bispecific antibody that binds simultaneously to type I Fc receptors for immunoglobulin G (IgG) (Fc gamma RI) and to the HER-2/neu oncogene protein product. MDX-210 effectively directs Fc gamma RI-positive effector cells such as monocytes and macrophages to phagocytose or kill tumor cells that overexpress HER-2/neu. The goals of this phase Ia/Ib trial were to determine the maximum-tolerated dose (MTD) and/or the optimal biologic dose (OBD) of MDX-210. Patients with advanced breast or ovarian cancer that overexpressed HER-2/neu were eligible for treatment. Cohorts of three patients received a single intravenous (IV) infusion of MDX-210 at increasing dose levels from 0.35 to 10.0 mg/m2. Treatment was well tolerated, with most patients experiencing transient grade 1 to 2 fevers, malaise, and hypotension only. Two patients experienced transient grade 3 hypotension at 10.0 mg/m2. Transient monocytopenia and lymphopenia developed at 1 to 2 hours, but no other hematologic changes were observed. Doses of MDX-210 > or = 3.5 mg/m2 saturated > or = 80% of monocyte Fc gamma RI and produced peak plasma concentrations > or = 1 microgram/mL, which is greater than the concentration for optimal monocyte/macrophage activation in vit...Continue Reading

Citations

Feb 1, 1997·Journal of Chemotherapy·E A TorreR A Fulco
Jan 1, 1997·International Reviews of Immunology·H RouardJ L Teillaud
Jan 7, 2000·Journal of Cellular Physiology·S MénardS M Pupa
Jul 19, 2001·Cancer Investigation·J S Ross, B J McKenna
Nov 5, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Lawrence G Lum, Archana Thakur
Feb 11, 2015·MAbs·Kipp Weiskopf, Irving L Weissman
Sep 2, 1999·International Journal of Cancer. Journal International Du Cancer·K A SmansJ L Millán
Mar 28, 2002·Human Gene Therapy·Kara L NormanPatrick W K Lee
Jan 13, 2006·Cancer Metastasis Reviews·Jeffrey S RossNeil H Bander
May 31, 2006·Cancer Immunology, Immunotherapy : CII·D RitchieH M Prince
Sep 1, 2008·Expert Opinion on Drug Discovery·Lawrence G Lum, Zaid Al-Kadhimi
Feb 6, 2016·Expert Opinion on Biological Therapy·Archana Thakur, Lawrence G Lum
Dec 26, 2015·Antibodies·Joanie Del BanoBrigitte Kerfelec
May 23, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·T KelerY M Deo
Jan 13, 2001·Oncogene·L M Weiner, G P Adams
Jan 1, 1997·International Reviews of Immunology·I A Heijnen, J G van de Winkel
Mar 17, 2001·International Journal of Cancer. Journal International Du Cancer·O ManzkeH Bohlen
Dec 18, 2007·Expert Opinion on Biological Therapy·Marjolein van Egmond
Oct 12, 2010·MAbs·Daniel R GettsStephen D Miller
Jul 1, 2010·Expert Review of Clinical Pharmacology·Jijie Gu, Tariq Ghayur
Apr 25, 2003·American Journal of Clinical Pathology·Jeffrey S RossMark Rolfe
Dec 17, 1997·International Journal of Cancer. Journal International Du Cancer·T BrodowiczC C Zielinski
Jul 5, 2005·Expert Opinion on Investigational Drugs·S Eccles
Feb 15, 1997·Medizinische Klinik·F Hartmann, M Pfreundschuh
Nov 4, 2011·Human Vaccines·Ching-Liang ChuChi-Chen Lin
Jun 20, 2018·Frontiers in Oncology·Christoph Renner, Frank Stenner
May 22, 2020·Journal of Drug Targeting·Vala KafilYadollah Omidi
May 9, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·A M McCallL M Weiner
Oct 10, 2002·Microscopy Research and Technique·Shahla Masood, Marilyn M Bui
Jan 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ursula ReuschLawrence G Lum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
William BlumGuido Marcucci
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Afshin DowlatiPingfu Fu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
J L MurrayR S Benjamin
© 2021 Meta ULC. All rights reserved